遠大醫藥(00512.HK):SIR-Spheres®釔[90Y]樹脂微球美國原發性肝癌臨試順利完成首例患者給藥
格隆匯 5 月 9日丨遠大醫藥(00512.HK)發佈公吿,集團的聯營公司Sirtex Medical Pty Ltd(“Sirtex”)的核心產品SIR-Spheres®釔[90Y]樹脂微球繼獲美國食品藥品管理局(“FDA”)批准開展原發性肝癌(“HCC”)臨牀試驗後,已於近期順利完成首例患者給藥。
集團將持續佈局抗腫瘤領域,以患者需求為核心,以科技創新為驅動,加大對放射性藥物和免疫抗腫瘤全球創新產品的投入,並聯合美國的OncoSec Medical Incorporated(NASDAQ:ONCS)、澳洲的Sirtex和Telix Pharmaceuticals Limited(ASX:TLX)三家全球領先的抗腫瘤醫藥公司,針對尚未滿足的臨牀需求,持續開發不同癌種的全球創新產品,豐富和完善產品管線及產業佈局,打造國際領先的放射性藥物和免疫抗腫瘤平台;採用“全球化運營佈局,雙循環經營發展”策略,形成國內國際雙循環聯動發展並相互促進的新格局,充分發揮本集團在國內的產業優勢和研發實力,快速將國際創新產品落地,為全球腫瘤患者提供更先進更多樣的治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.